In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab 'may be a new standard' and more. Read the full coverage here: FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be 'a new standard' Perioperative nivolumab improves outcomes in resectable NSCLC Despite progress, barriers to lung cancer biomarker testing persist Atezolizumab regimen 'merits further study' for unresectable NSCLC References: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Press Release Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897. Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Ver todos los episodios